Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
Marcia S. Brose, Bruce Robinson, Steven I. Sherman, Jolanta Krajewska, Chia‐Chi Lin, Fernanda Vaisman, Ana O. Hoff, Erika Hitre, Daniel W. Bowles, Jorge Hernando, Leonardo Faoro, Kamalika Banerjee, Jennifer Oliver, Bhumsuk Keam, Jaume Capdevila
Topics & Concepts
LenvatinibMedicineCabozantinibInternal medicineSorafenibPopulationPlaceboOncologyThyroid cancerInterim analysisResponse Evaluation Criteria in Solid TumorsClinical trialCancerSurgeryPhases of clinical researchPathologyHepatocellular carcinomaAlternative medicineEnvironmental healthThyroid Cancer Diagnosis and TreatmentRenal cell carcinoma treatmentThyroid and Parathyroid Surgery